<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02684136</url>
  </required_header>
  <id_info>
    <org_study_id>FM16</org_study_id>
    <nct_id>NCT02684136</nct_id>
  </id_info>
  <brief_title>Suvorexant in Insomnia Co-morbid With Fibromyalgia</brief_title>
  <official_title>A Double-blind, Crossover, Study to Compare the Hypnotic, Daytime Sleepiness/Fatigue, and Pain Effects of Nighttime Administration of Suvorexant 20 mg Versus Placebo in Patients With Fibromyalgia and Comorbid Insomnia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Henry Ford Health System</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Henry Ford Health System</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will compare sleep, pain and daytime sleepiness/fatigue in people with insomnia&#xD;
      co-morbid with fibromyalgia while treated short-term with suvorexant 20 mg versus placebo.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It has now become clear that the relation of sleep and pain is bidirectional; acute and&#xD;
      chronic pain is associated with disturbed sleep and disturbed sleep enhances pain.&#xD;
      Experimental studies have shown that reduced and fragmented sleep in pain-free normals&#xD;
      increases their pain sensitivity and daily self-report studies in chronic pain patients have&#xD;
      shown a poor night of sleep is followed by enhanced next-day pain. In mediation analyses of&#xD;
      large clinical data sets it is found that the sleep-pain side of the bidirectional relation,&#xD;
      as opposed to the pain-sleep side, accounts for the greater variance. These data then would&#xD;
      suggest that improving sleep in chronic pain disorders should attenuate daytime pain.&#xD;
&#xD;
      Most of the drugs used to treat chronic pain facilitate inhibitory central nervous system&#xD;
      mechanisms as their primary mechanism of action. Suvorexant, recently approved by the FDA for&#xD;
      the treatment of insomnia characterized by difficulties with sleep onset and sleep&#xD;
      maintenance, has a unique mechanism of action. Suvorexant is a selective antagonist for&#xD;
      orexin receptors (OX1R and OX2R). Orexins are considered to be involved in arousal and&#xD;
      maintenance of the waking state.&#xD;
&#xD;
      As such, suvorexant may provide unique clinical benefit as a treatment in chronic pain&#xD;
      conditions with co-morbid insomnia, and specifically for fibromyalgia with its putative&#xD;
      central hyperarousal and hypersensitization. Thus, this project proposes to study objective&#xD;
      and clinical measures of sleep, pain, and daytime sleepiness and fatigue in patients with&#xD;
      fibromyalgia and co-morbid insomnia while treated short-term with suvorexant 20 mg versus&#xD;
      placebo.&#xD;
&#xD;
      Those qualifying will receive suvorexant 20 mg and placebo for each of 9 nights in a cross&#xD;
      over design with 7 nights of washout between treatments. Overnight sleep recordings (PSGs)&#xD;
      will be collected on nights 7 and 8 of each crossover treatment arm to determine objective&#xD;
      sleep measures. During the day following night 7 in each arm, a Multiple Sleep Latency Test&#xD;
      (MSLT) at 1000, 1200, 1400, and 1600 hr will be conducted and nociceptive sensitivity [finger&#xD;
      withdrawal latency (FWL)] testing to a radiant heat stimulus (1100 and 1500 hr) will be&#xD;
      conducted on day 1 and day 8. Self-reported mood and pain indices will also be completed&#xD;
      prior to each FWL test.&#xD;
&#xD;
      Primary outcomes to be measured include PSG sleep efficacy and FWL response on both&#xD;
      conditions (suvorexant 20 mg versus placebo).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    reduced ability to recruit sufficient number of patients&#xD;
  </why_stopped>
  <start_date>February 1, 2016</start_date>
  <completion_date type="Actual">July 1, 2018</completion_date>
  <primary_completion_date type="Actual">July 1, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Polysomnographic Assessment of Sleep</measure>
    <time_frame>continuous sleep recording from 11pm to 7am on night 8</time_frame>
    <description>total sleep time on 8 hr standard sleep recording</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Daytime Pain Sensitivity</measure>
    <time_frame>mean of tests at 1100 and 1500 hrs on both day 1 and day 8</time_frame>
    <description>finger withdrawal response to a radiant heat stimulus when pain is first experienced</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Insomnia</condition>
  <condition>Fibromyalgia</condition>
  <arm_group>
    <arm_group_label>suvorexant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>9 nights of 20 mg suvorexant</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>9 nights placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>suvorexant</intervention_name>
    <description>suvorexant 20 mg taken before sleep</description>
    <arm_group_label>suvorexant</arm_group_label>
    <other_name>belsomra</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo taken before sleep</description>
    <arm_group_label>placebo</arm_group_label>
    <other_name>matching placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  meet Diagnostic and Statistical Manual 5th ed criteria for insomnia&#xD;
&#xD;
          -  meet American College of Rheumatology criteria for fibromyalgia&#xD;
&#xD;
          -  otherwise good psychiatric and stable physical health&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  other primary sleep disorders&#xD;
&#xD;
          -  pain symptoms unrelated to fibromyalgia&#xD;
&#xD;
          -  current pregnancy or breast-feeding&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Timothy Roehrs, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Henry Ford Health System</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Thomas Roth, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Henry Ford Health System</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>HFHS Sleep Disorders Ctr</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Wolfe F, Clauw DJ, Fitzcharles MA, Goldenberg DL, Katz RS, Mease P, Russell AS, Russell IJ, Winfield JB, Yunus MB. The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care Res (Hoboken). 2010 May;62(5):600-10. doi: 10.1002/acr.20140.</citation>
    <PMID>20461783</PMID>
  </reference>
  <reference>
    <citation>Roehrs T, Diederichs C, Gillis M, Burger AJ, Stout RA, Lumley MA, Roth T. Nocturnal sleep, daytime sleepiness and fatigue in fibromyalgia patients compared to rheumatoid arthritis patients and healthy controls: a preliminary study. Sleep Med. 2013 Jan;14(1):109-15. doi: 10.1016/j.sleep.2012.09.020. Epub 2012 Nov 11.</citation>
    <PMID>23149217</PMID>
  </reference>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>January 22, 2016</study_first_submitted>
  <study_first_submitted_qc>February 11, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 17, 2016</study_first_posted>
  <results_first_submitted>August 22, 2019</results_first_submitted>
  <results_first_submitted_qc>April 5, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">April 28, 2021</results_first_posted>
  <last_update_submitted>May 26, 2021</last_update_submitted>
  <last_update_submitted_qc>May 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Henry Ford Health System</investigator_affiliation>
    <investigator_full_name>Timothy Roehrs, PhD</investigator_full_name>
    <investigator_title>Senior Bioscientist</investigator_title>
  </responsible_party>
  <keyword>insomnia</keyword>
  <keyword>fibromyalgia</keyword>
  <keyword>polysomnography</keyword>
  <keyword>pain management</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibromyalgia</mesh_term>
    <mesh_term>Myofascial Pain Syndromes</mesh_term>
    <mesh_term>Sleep Initiation and Maintenance Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Suvorexant</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 10, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/36/NCT02684136/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Suvorexant First, Then Placebo</title>
          <description>9 nights of 20 mg suvorexant first, then 9 nights of placebo suvorexant: suvorexant 20 mg taken before sleep; placebo taken before sleep</description>
        </group>
        <group group_id="P2">
          <title>Placebo First, Then Suvorexant</title>
          <description>9 nights placebo first, washout, then 9 nights of 20 mg suvorexant: suvorexant 20 mg taken before sleep; placebo taken before sleep</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Intervention (9 Nights)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Washout (7 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Second Intervention (9 Nights)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>this is a crossover study</population>
      <group_list>
        <group group_id="B1">
          <title>All Study Participants</title>
          <description>this is a crossover study with 20 mg suvorexant and placebo each administered for 9 nights</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50.1" spread="9.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Total Sleep Time</title>
          <description>minutes of total sleep time on a 8-hr PSG</description>
          <units>min of total sleep time on a 8-hr PSG</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="346.9" spread="52.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Polysomnographic Assessment of Sleep</title>
        <description>total sleep time on 8 hr standard sleep recording</description>
        <time_frame>continuous sleep recording from 11pm to 7am on night 8</time_frame>
        <population>this is crossover study so all 10 Ss received both placebo and suvorexant</population>
        <group_list>
          <group group_id="O1">
            <title>Suvorexant</title>
            <description>9 nights of 20 mg suvorexant&#xD;
suvorexant: suvorexant 20 mg taken before sleep</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>9 nights placebo&#xD;
placebo: placebo taken before sleep</description>
          </group>
        </group_list>
        <measure>
          <title>Polysomnographic Assessment of Sleep</title>
          <description>total sleep time on 8 hr standard sleep recording</description>
          <population>this is crossover study so all 10 Ss received both placebo and suvorexant</population>
          <units>min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="429.3" spread="29.4"/>
                    <measurement group_id="O2" value="400.5" spread="57.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>ANCOVA</method>
            <method_desc>baseline used as covariate</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Daytime Pain Sensitivity</title>
        <description>finger withdrawal response to a radiant heat stimulus when pain is first experienced</description>
        <time_frame>mean of tests at 1100 and 1500 hrs on both day 1 and day 8</time_frame>
        <population>this is a crossover study so all 10 Ss received placebo and suvorexant</population>
        <group_list>
          <group group_id="O1">
            <title>Suvorexant</title>
            <description>9 nights of 20 mg suvorexant&#xD;
suvorexant: suvorexant 20 mg taken before sleep</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>9 nights placebo&#xD;
placebo: placebo taken before sleep</description>
          </group>
        </group_list>
        <measure>
          <title>Daytime Pain Sensitivity</title>
          <description>finger withdrawal response to a radiant heat stimulus when pain is first experienced</description>
          <population>this is a crossover study so all 10 Ss received placebo and suvorexant</population>
          <units>sec</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.8" spread="5.4"/>
                    <measurement group_id="O2" value="14.7" spread="4.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <p_value_desc>baseline used as covariate</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>nightly over the 9 nights</time_frame>
      <desc>this is a crossover study and all 10 Ss were at risk in the placebo and suvorexant arms</desc>
      <group_list>
        <group group_id="E1">
          <title>Suvorexant</title>
          <description>9 nights of 20 mg suvorexant&#xD;
suvorexant: suvorexant 20 mg taken before sleep</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>9 nights placebo&#xD;
placebo: placebo taken before sleep</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>headache</sub_title>
                <description>headache, dizziness, residual sedation - adverse event terms can not be separated</description>
                <counts group_id="E1" events="17" subjects_affected="8" subjects_at_risk="10"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Study closed after 18 moinths due to difficulty recruiting additional subjects beyond the 10 completed.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Timothy Roehrs PhD Study Investigator</name_or_title>
      <organization>HenryFordHS</organization>
      <phone>313-916-5177</phone>
      <email>troehrs1@hfhs.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

